Ryan F. Quarles: “It is not our intention. Indeed, it is the opposite of our intention, to affect the total loss-absorbing capacity of the…”

The FDA needs to provide regulatory pathways for products containing CBD. The FDA needs to act now.

If there is a credit allocation decision to be made, that is a decision for Congress, to be debated by the public's representatives.

I do think that a legislature is in a better position to resist the slippery slope for that solution.

Similarly, that has always been a high priority of the Federal Reserve, and where we have the enforcement authority to act, we will do that.